Résume l'activité d'Oria Bioscience en 1 phrase

Maintenant décrit le projet en moins de 800 mots

Traduit en francais et coupe le en moins de 800 mots

Traduit en francais et coupe en moisn de 800 mots : Organelles (nucleus, lysosome, mitochondria, etc.) are compartments located inside the cell, hardly accessible. Only 10% of drugs act on organelle proteins, even though they are five times more numerous than external membrane targets. Currently, it is impossible for laboratories to screen drug candidates targeting organelle targets, at high-throughput. Organelles are difficult to access, and Drug Discovery efficacy tests are unreliable. At Oria, we are developing the first high-throughput organelle purification method in microfluidics, keeping their native target activity and compatible with High Throughput Screening methods. This technology, intended for pharmaceutical laboratories and drug discovery CROs will allow them to perform lysosomal screening 100 times faster on First-In-Class Targets for neurodegenerative diseases, cancers and cardiovascular diseases. Oria is a spin-off company from ENS Paris - CNRS. Its microfluidic technology, 3-times patented, was developed by Alexandre Santinho (CEO) and Abdou-Rachid Thiam (CSO) in 2021. Marine Moutia (COO) joined them in 2022 to consolidate the business aspects. Since 2021, 600k€ of non-dilutive ante creation funds have been dedicated to the project allowing the recruitment of a R&D team (3 PhD holders) and the first industrial POC. A fundraise of 2M€ to 3M€ (50% dilutive) is planned for September 2024 (closing for March 2025) to commercialize our first product : high quality purified lysosomes, to European CROs and Pharmaceutical Laboratories.